CellSource Co

CellSource Co Free Cash Flow

The Free Cash Flow (FCF) of CellSource Co (4880.T) as of Oct 27, 2026 is 289.91 M JPY. In the previous year, Free Cash Flow (FCF) was 98.47 M JPY — a change of 194.42% (higher).

Free Cash Flow

289.91 MJPY

YoY

194.42%

Last updated:

Free Cash Flow (FCF) of CellSource Co is 2025 289.91 M JPY. Free Cash Flow (FCF) of CellSource Co was 2024 98.47 M JPY. It decreases by 194.42% higher compared to the previous year.

The CellSource Co Free Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Free Cash Flow
Date
Free Cash Flow
Jan 1, 2018
189.08 M JPY
Jan 1, 2019
145.21 M JPY
Jan 1, 2020
300.15 M JPY
Jan 1, 2021
843.36 M JPY
Jan 1, 2022
752.89 M JPY
Jan 1, 2023
498.62 M JPY
Jan 1, 2024
98.47 M JPY
Jan 1, 2025
289.91 M JPY
The CellSource Co Free Cash Flow history
YEARFree Cash FlowYoY
289.91 MJPY+194.42%
98.47 MJPY-80.25%
498.62 MJPY-33.77%
752.89 MJPY-10.73%
843.36 MJPY+180.98%
300.15 MJPY+106.70%
145.21 MJPY-23.20%
189.08 MJPY+85.25%
102.07 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSource Co Stock analysis

What does CellSource Co do? CellSource Co., Ltd. generates revenue through its Regenerative Medicine Related business segment, which provides contracted services for processing tissues and cells from fat and blood to medical institutions, along with support services for regenerative medicine laws and regulations related to safety assurance. The company also sells medical equipment within this segment. The Consumer business segment focuses on selling cosmetics and facial products directly to general consumers. Both segments operate under the company's brand without additional brand names mentioned in the description. The Regenerative Medicine Related business segment targets medical institutions and regulatory compliance support for regenerative medicine safety, while the Consumer business segment serves general consumers seeking cosmetics and facial care products. The company's products include processed tissue and cell services, regulatory support, medical equipment, and consumer skincare items, all sold under the CellSource brand. CellSource Co., Ltd. employs 109 full-time employees to manage its two business segments, with the Regenerative Medicine Related segment handling medical services and equipment sales, and the Consumer segment focusing on direct-to-consumer product sales. The company's revenue streams are derived from these two distinct operational areas without any additional external partnerships or third-party brands. CellSource Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CellSource Co stock

Free Cash Flow (FCF) of CellSource Co is 289.91 M JPY in 2025.

Free Cash Flow (FCF) of CellSource Co changed from 98.47 M JPY to 289.91 M JPY, representing a 194.42% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow (FCF) CellSource Co since 2006 – with annual values, charts, and detailed analysis.

Free Cash Flow is the cash available after capital expenditures. It represents the cash a company can use for dividends, debt reduction, or reinvestment.

FCF = Operating Cash Flow - Capital Expenditures

Free Cash Flow (FCF)'s JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Free Cash Flow (FCF)'s CellSource Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — CellSource Co

All Key Metrics — CellSource Co